BMY

Investors can buy low cost index fund if they want to receive the average market return. But if you invest in...

Is BMY stock a buy after Bristol Myers Squibb said a cancer drug called Breyanzi outperformed the standard treatment in patients with a form of lymphoma?

Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.

Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

PRINCETON, N.J., Jun 18, 2021--BMS Receives European Commission Approval for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody-drug conjugate (ADC). Bristol Myers will pay $650 million, including $200 million to Eisai's R&D efforts, for shared global rights to MORAb-202, the Japanese company's first ADC, which is a combination between an in-house folate receptor antibody and chemotherapy eribulin, marketed as Ha

Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug. Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.

Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.

TOKYO & NEW YORK, Jun 17, 2021--Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

NEW YORK, Jun 17, 2021--Bristol Myers Squibb Announces Dividend

On Thursday, the Supreme Court released its highly anticipated decision on a challenge to the Affordable Care Act (ACA), also known as Obamacare. By a 7-2 vote, the court rejected the Republican-led challenge to the law.

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the Darzalex combo in patients with newly diagnosed multiple myeloma. After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed. Adding Darzalex (daratumumab) to Bristol-Myers Squibb Co’s (NYSE: BMY) Revlimid (lenalidomide) and steroid dexamethasone (Rd) could slash the

Depending on your risk tolerance and investment preferences, there are a number of smart ways to put your money to work.

Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis. In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli discuss just how big this FDA win is for Bristol Myers Squibb.

Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.

PRINCETON, N.J. & CAMBRIDGE, Mass., Jun 11, 2021--BMS & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia

Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience

By Yasin Ebrahim